RS52710B - Treatment of cartilage disorders with FGF-18 - Google Patents

Treatment of cartilage disorders with FGF-18

Info

Publication number
RS52710B
RS52710B RS20120483A RSP20120483A RS52710B RS 52710 B RS52710 B RS 52710B RS 20120483 A RS20120483 A RS 20120483A RS P20120483 A RSP20120483 A RS P20120483A RS 52710 B RS52710 B RS 52710B
Authority
RS
Serbia
Prior art keywords
fgf
treatment
cartilage disorders
administered
compound
Prior art date
Application number
RS20120483A
Other languages
English (en)
Serbian (sr)
Inventor
Alberto Gimona
Christoph H. Ladel
Elmar Vom Baur
Original Assignee
Ares Trading S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading S.A. filed Critical Ares Trading S.A.
Priority claimed from PCT/EP2007/058830 external-priority patent/WO2008023063A2/en
Publication of RS52710B publication Critical patent/RS52710B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20120483A 2006-08-25 2007-08-24 Treatment of cartilage disorders with FGF-18 RS52710B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06119557 2006-08-25
US84060006P 2006-08-28 2006-08-28
PCT/EP2007/058830 WO2008023063A2 (en) 2006-08-25 2007-08-24 Treatment of cartilage disorders with fgf-18

Publications (1)

Publication Number Publication Date
RS52710B true RS52710B (en) 2013-08-30

Family

ID=37684849

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20120483A RS52710B (en) 2006-08-25 2007-08-24 Treatment of cartilage disorders with FGF-18

Country Status (11)

Country Link
CN (1) CN101505787B (da)
BR (1) BRPI0715728A8 (da)
DK (1) DK2054050T3 (da)
ES (1) ES2392883T3 (da)
MY (1) MY148277A (da)
NZ (1) NZ574216A (da)
PT (1) PT2054050E (da)
RS (1) RS52710B (da)
SI (1) SI2054050T1 (da)
UA (1) UA99818C2 (da)
ZA (1) ZA200900426B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2880179B1 (en) * 2012-08-06 2017-12-13 Merck Patent GmbH Genetic markers for predicting responsiveness to fgf-18 compound
EP3107591B1 (en) * 2014-02-20 2018-04-18 Merck Patent GmbH Fgf-18 in graft transplantation and tissue engineering procedures
PL3107592T3 (pl) * 2014-02-20 2019-02-28 Merck Patent Gmbh Implant zawierający FGF-18
MX2016010872A (es) * 2014-02-20 2016-11-17 Merck Patent Gmbh Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18.
WO2016112176A1 (en) * 2015-01-08 2016-07-14 University Of Iowa Research Foundation Methods for the regeneration of articular cartilage in vivo
EP3957654A1 (en) * 2015-07-15 2022-02-23 Prosit Sole Biotechnology (Beijing) Co., Ltd Fusion polypeptides and methods of use
US20180236032A1 (en) * 2015-08-13 2018-08-23 Merck Patent Gmbh Combination composition comprising fgf-18 compound
CA3162235A1 (en) * 2019-11-21 2021-05-27 Remedium Bio, Inc. Growth factor restoration
US11904006B2 (en) 2019-12-11 2024-02-20 University Of Iowa Research Foundation Poly(diaminosulfide) particle-based vaccine
CN117721115A (zh) * 2022-09-06 2024-03-19 深圳瑞吉生物科技有限公司 用于治疗骨关节炎的mRNA及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2493840T3 (es) * 2002-10-07 2014-09-12 Zymogenetics, Inc. Procedimiento de administración de FGF-18
EP1896053B1 (en) * 2004-07-06 2018-10-31 ZymoGenetics, Inc. Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use
US7858341B2 (en) * 2004-12-10 2010-12-28 Zymogenetics, Inc. FGF18 production in prokaryotic hosts

Also Published As

Publication number Publication date
BRPI0715728A8 (pt) 2018-04-03
BRPI0715728A2 (pt) 2013-09-17
CN101505787A (zh) 2009-08-12
DK2054050T3 (da) 2012-09-03
PT2054050E (pt) 2012-09-17
MY148277A (en) 2013-03-29
UA99818C2 (ru) 2012-10-10
ES2392883T3 (es) 2012-12-14
NZ574216A (en) 2011-11-25
SI2054050T1 (sl) 2012-12-31
ZA200900426B (en) 2010-04-28
CN101505787B (zh) 2013-09-04

Similar Documents

Publication Publication Date Title
RS52710B (en) Treatment of cartilage disorders with FGF-18
CY1122076T1 (el) Φυτικα εκχυλισματα που περιεχουν κανναβινοειδες σαν νευρο-προστατευτικοι παραγοντες
UA108832C2 (uk) Комбінації кон'югата анти-her2-антитіло-лікарський засіб і хіміотерапевтичних засобів і способи застосування
RS53513B1 (en) GLYX-13 FOR USE IN THE REFRACTOR DEPRESSION TREATMENT PROCEDURE
RS51185B (sr) Kompozicije za vaginalnu primenu
RS54372B1 (en) COLLAGENASIS FOR TREATMENT OF CELLULITE
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
BRPI0418384A (pt) composições farmacêuticas e métodos referentes à inibição de adesões fibrosas utilizando diversos agentes
CR10166A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania
MY155633A (en) Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy
DOP2009000272A (es) Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa y kit
MX2010001849A (es) Depsipeptidos ciclicos.
EP1907014A4 (en) CHONDROGENIC COMPOSITIONS AND METHODS OF USE
RS52251B (en) PPAR-GAMA Agonists for Induction of Expression of Cationic Antimicrobial Peptide as Immune-Protective Stimulants
RS52821B (en) LONG-TERM TREATMENT OF HIV INFECTION WITH TCM278
RS54265B1 (en) ADHESIVE CAPSULITIS TREATMENT PROCEDURES
MY168759A (en) Pharmaceutical compositions comprising modified fucans and methods relating thereto
TW200716616A (en) Modulators of CCR-5 activity
ATE530188T1 (de) Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs
MX2009007384A (es) Formulaciones que contienen ?-lactama con elevada estabilidad en disolucion acuosa.
ATE538799T1 (de) Zusammensetzungen zur behandlung von haarverlust
NZ609440A (en) Preventative or therapeutic agent for fibrosis
BR112012006070A2 (pt) composições e métodos para tratar distúrbios convulsivos.
EA200801678A1 (ru) Применение производных триазина для производства лекарственного средства, обладающего заживляющим или ангиогенным эффектом
AR059636A1 (es) Metodo y composicion para tratar la enfermedad pulmonar obstructiva cronica